Business Description
Taysha Gene Therapies Inc
NAICS : 541714
SIC : 2834
ISIN : US8776191061
Share Class Description:
TSHA: Ordinary SharesTotal Employee Number:
99Description
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.04 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.32 | |||||
Debt-to-EBITDA | -0.53 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 8.95 | |||||
Beneish M-Score | -2.66 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -18.4 | |||||
3-Year EBITDA Growth Rate | 54.9 | |||||
3-Year EPS without NRI Growth Rate | 51.5 | |||||
3-Year FCF Growth Rate | 51.6 | |||||
3-Year Book Growth Rate | 286.5 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 187.87 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.88 | |||||
9-Day RSI | 47.9 | |||||
14-Day RSI | 51.04 | |||||
3-1 Month Momentum % | 20.27 | |||||
6-1 Month Momentum % | 8.43 | |||||
12-1 Month Momentum % | 111.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 14.04 | |||||
Quick Ratio | 14.04 | |||||
Cash Ratio | 13.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -65.2 | |||||
Shareholder Yield % | -0.3 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -1774.37 | |||||
Net Margin % | -1738.4 | |||||
EBITDA Margin % | -1722.21 | |||||
FCF Margin % | -1543.73 | |||||
OCF Margin % | -1498.43 | |||||
ROE % | -66.15 | |||||
ROA % | -45.35 | |||||
ROIC % | -455.33 | |||||
3-Year ROIIC % | -39.99 | |||||
ROC (Joel Greenblatt) % | -853.05 | |||||
ROCE % | -49.6 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 288.16 | |||||
PB Ratio | 8.57 | |||||
Price-to-Tangible-Book | 8.57 | |||||
EV-to-EBIT | -12.43 | |||||
EV-to-EBITDA | -12.54 | |||||
EV-to-Revenue | 216.01 | |||||
EV-to-Forward-Revenue | 126.37 | |||||
EV-to-FCF | -13.99 | |||||
Price-to-GF-Value | 9.19 | |||||
| Price-to-Net-Current-Asset-Value | 9.46 | |||||
| Price-to-Net-Cash | 9.61 | |||||
Earnings Yield (Greenblatt) % | -8.05 | |||||
FCF Yield % | -6.33 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TSHA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Taysha Gene Therapies Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 7.471 | ||
| EPS (TTM) ($) | -0.38 | ||
| Beta | 0.5514 | ||
| 3-Year Sharpe Ratio | 0.81 | ||
| 3-Year Sortino Ratio | 4.12 | ||
| Volatility % | 70.19 | ||
| 14-Day RSI | 51.04 | ||
| 14-Day ATR ($) | 0.40831 | ||
| 20-Day SMA ($) | 6.38 | ||
| 12-1 Month Momentum % | 111.76 | ||
| 52-Week Range ($) | 2.34 - 7.3 | ||
| Shares Outstanding (Mil) | 287.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Taysha Gene Therapies Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Taysha Gene Therapies Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-04 08:30 | In 117 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 116 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 08:30 | In 33 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 32 days | ||
| TSHA-102 Rett Syndrome Program Update Conference Call | 2026-06-22 08:30 | 6.42 (+2.80%) | ||
| General meeting for 2026 | 2026-06-01 09:00 | 5.86 (-1.26%) | ||
| First quarter earnings conference call for 2026 | 2026-05-06 08:30 | 6.94 (+3.27%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 6.94 (+3.27%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-19 08:30 | 4.45 (-1.77%) | ||
| Annual report for 2025 | 2026-03-19 | 4.45 (-1.77%) |
Show
Entries
Taysha Gene Therapies Inc Frequently Asked Questions
What is Taysha Gene Therapies Inc(TSHA)'s stock price today?
The current price of TSHA is $6.34. The 52 week high of TSHA is $7.30 and 52 week low is $2.34.
When is next earnings date of Taysha Gene Therapies Inc(TSHA)?
The next earnings date of Taysha Gene Therapies Inc(TSHA) is 2026-08-12 Est..
Does Taysha Gene Therapies Inc(TSHA) pay dividends? If so, how much?
Taysha Gene Therapies Inc(TSHA) does not pay dividend.
Guru Commentaries on NAS:TSHA
No articles.
Press Release
Articles on Taysha Gene Therapies Inc
Insider Sell: Sukumar Nagendran Sells 200,000 Shares of Taysha Gene Therapies Inc (TSHA)
22 hours ago
Headlines
See More- 1
Jun 25, 2026
At a glance: stocks gapping down premarket
Seeking Alpha • 6:28am
Taysha Gene Therapies shares tumble following pricing shares at $6.00 to raise $200M
Seeking Alpha • 1:38am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers